FOLD - Latest News

Amicus Therapeutics, Inc. (FOLD), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $4.55B. Beta to the broader market is 0.48.

The article list below shows the most recent FOLD headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent FOLD Headlines

BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition

seekingalpha.com - May 6, 2026

BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition

CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)

fool.com - Apr 25, 2026

Amicus Therapeutics targets rare genetic diseases with proprietary therapies and a pipeline of treatments for underserved patient groups.

BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy

seekingalpha.com - Apr 15, 2026

BioMarin (BMRN) has declined over 12% since January 2025, despite prior optimism. The investment thesis centers on the potential of VOXZOGO and Amicu

SG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLD

defenseworld.net - Apr 7, 2026

SG Americas Securities LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 53.

Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD

defenseworld.net - Apr 6, 2026

Capricorn Fund Managers Ltd bought a new stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) during the undefined quarter, according to the company in

How News Affects FOLD Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track FOLD's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.